ストックスクリーナーアプリを入手
2.06
4.41%
-0.095
アフターアワーズ：
2.02
-0.04
-1.94%
Xortx Therapeutics Inc (XRTX) 最新ニュース
XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet - TipRanks
Going-concern warning at XORTX (XRTX) as losses mount - Stock Titan
XORTX Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo - The Globe and Mail
Board chair exit at XORTX Therapeutics (NASDAQ: XRTX) detailed - Stock Titan
XORTX Therapeutics (XRTX) Climbs 4.92% as Shares Approach Key Resistance at $2.23Fibonacci Retracement - dars.gov.et
XORTX Therapeutics (XRTX) Climbs 4.92% to $2.12 as Speculative Interest BuildsSwing Entry Signals - dars.gov.et
XORTX Therapeutics Inc. Announces Resignation of Anthony Giovinazzo from Director Role - marketscreener.com
XORTX Director Anthony Giovinazzo Steps Down for Personal Reasons - Stock Titan
XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight - TipRanks
XORTX Therapeutics (NASDAQ: XRTX) appoints Depesh Narotam as independent director - Stock Titan
XORTX Appoints New Director - GlobeNewswire
XORTX Board Gains Director With Over 20 Years in Financial Services - Stock Titan
Vectus Biosystems Appoints Dr Tara Speranza as CEO and CTO, Raises $791,000 to Accelerate VB0004 Clinical Development - Kalkine
Why XORTX Therapeutics Inc stock is sliding today - Wealth Awesome
XORTX Therapeutics Inc (XRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XORTX Therapeutics Inc (XRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XRTX|XORTX Therapeutics Inc|Price:2.025|Chg%:-0.090 - TradingKey
XRTX|XORTX Therapeutics Inc|Price:2.015|Chg%:-0.010 - TradingKey
XORTX Therapeutics Inc (XRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
XORTX Therapeutics Inc (XRTX) Institutional Confidence - TradingKey
XORTX Therapeutics Inc (XRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XORTX Therapeutics Inc (XRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XORTX Therapeutics Inc. Revenue Breakdown – NASDAQ:XRTX - TradingView
XORTX Therapeutics Inc (XRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XORTX Therapeutics, Inc. Revenue Breakdown – NEO:XRTX - TradingView
XORTX Therapeutics(XRTX) Stock Options Chain | Quotes & News - Moomoo
XORTX Therapeutics (XRTX) Investor presentation Summary - Quartr
XORTX Therapeutics (XRTX) Q4 2024 earnings summary - Quartr
Price to earnings forward of XORTX Therapeutics, Inc. – LSX:A427MJ - TradingView
XORTX Therapeutics (XRTX) Rallies 3.3% as Biotech Sector Gains MomentumMoney Flow - dars.gov.et
XORTX Therapeutics (XRTX) Gains 3.33% as Biotech Momentum BuildsDescending Triangle - dars.gov.et
XRTX Q1 2024 Earnings: Pre‑Revenue Biotech Reports EPS Miss as Clinical Pipeline AdvancesDiluted EPS Report - dars.gov.et
XORTX Therapeutics Inc. (XRTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Xortx Therapeutics updates investors on kidney disease focus - ad-hoc-news.de
XORTX Therapeutics Company Profile & Introduction - Moomoo
XRTX Q1 2024 Earnings: Significant EPS Miss Reflects Preclinical Stage ChallengesQuarterly Earnings - dars.gov.et
Enterprise value to EBIT forward of XORTX Therapeutics, Inc. – TSXV:XRTX - TradingView
Price to sales forward of XORTX Therapeutics, Inc. – TSXV:XRTX - TradingView
Enterprise value to revenue forward of XORTX Therapeutics, Inc. – TSXV:XRTX - TradingView
Why XORTX Therapeutics Inc stock is skyrocketing today - Wealth Awesome
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
XRTX Q1 2024 Earnings: Significant EPS Miss Highlights Challenges in Clinical-Stage BiotechEarnings Growth Analysis - dars.gov.et
XRTX Q1 2024 Earnings: Significant EPS Miss Amid Operational DevelopmentsEarnings Surprise Stocks - DonanımHaber
XORTX Therapeutics (XRTX) Edges Higher as Stock Remains Within Defined RangeLong Short Pair - DonanımHaber
XORTX Therapeutics Inc. (XRTX) Slides 2.79% as Shares Test Key Support Near $2.00Flat Correction - dars.gov.et
XORTX Therapeutics Inc (XRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XORTX Therapeutics Inc (XRTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
XORTX Therapeutics Q1 2024 Earnings: Significant EPS Miss Reflects R&D Investment, Stock Gains Despite Loss - newsline.com
XORTX Therapeutics (XRTX) Gains 1.43% as Shares Approach Resistance at $2.24Virgin POC - dars.gov.et
XORTX Therapeutics (XRTX) Slips 0.68% as Traders Eye Key Support at $2.06Covered Call ETF - newsline.com
XORTX Therapeutics appoints Mika Grasso as co‑CEO - MSN
XORTX Therapeutics Appoints Mika Grasso as Co-CEO; Voluntarily Delisting from the TSX Venture Exchange - marketscreener.com
XORTX Therapeutics Inc. Announces Appointment of Mika Grasso to Co-CEO - marketscreener.com
XORTX Therapeutics Providing Corporate Update and Appoints Mika Grasso as Co-CEO - marketscreener.com
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):